Melatan: Uses, Dosage & Side Effects

What Is Melatan and What Is It Used For?

Melatan contains melatonin as its active ingredient, a naturally occurring indoleamine hormone (chemically known as N-acetyl-5-methoxytryptamine) that is synthesized primarily in the pineal gland of the brain. Melatonin production follows a distinct circadian pattern: levels begin to rise in the evening approximately two hours before habitual bedtime (a period known as the dim light melatonin onset, or DLMO), peak during the middle of the night (typically between 2:00 AM and 4:00 AM), and decline to low daytime levels by early morning. This rhythmic secretion pattern is controlled by the suprachiasmatic nucleus (SCN) of the hypothalamus, the body's master biological clock, which receives light input via the retinohypothalamic tract from specialized intrinsically photosensitive retinal ganglion cells (ipRGCs) in the eye.

The physiological role of melatonin extends beyond simple sleep promotion. It serves as a chronobiotic agent, meaning it communicates time-of-day information to the body's peripheral organs and tissues, synchronizing a wide array of biological processes including core body temperature regulation, cortisol secretion, immune function, and metabolic activity with the environmental light-dark cycle. Melatonin exerts its sleep-promoting effects primarily through two G-protein coupled receptors: MT1 (or MTNR1A) and MT2 (or MTNR1B). Activation of MT1 receptors in the SCN promotes sleepiness by inhibiting the firing of wake-promoting neurons, while activation of MT2 receptors helps shift and entrain the circadian clock, facilitating the proper timing of sleep onset.

With advancing age, endogenous melatonin production typically declines. Studies have consistently shown that nocturnal melatonin levels are significantly lower in individuals over the age of 55 compared with younger adults, and this decline in melatonin secretion has been correlated with increased prevalence of sleep difficulties in older populations. Additionally, the amplitude of the melatonin rhythm may become blunted, and the timing of peak secretion may shift, contributing to circadian misalignment. Melatan addresses this physiological deficit by providing exogenous melatonin that supplements the body's diminished production, thereby restoring the circadian signal for sleep.

Melatan is indicated for the short-term treatment of primary insomnia characterized by poor quality of sleep. Primary insomnia refers to sleep difficulty that is not attributable to another medical condition, psychiatric disorder, medication effect, or substance use. The European Medicines Agency (EMA) has specifically approved prolonged-release melatonin formulations for patients aged 55 years and older, recognizing the age-related decline in melatonin as a contributing factor to insomnia in this population. However, melatonin is also used clinically for a broader range of sleep-related indications, including:

• Jet lag: Melatonin is one of the most well-studied treatments for jet lag, particularly for eastward travel across multiple time zones. Taking melatonin at the destination's bedtime helps resynchronize the circadian clock to the new time zone. A Cochrane review found that melatonin taken close to the target bedtime at the destination significantly reduced self-rated jet lag severity.
• Shift work disorder: Workers who rotate between day and night shifts often experience disrupted circadian rhythms. Melatonin can help promote daytime sleep when taken before the intended sleep period and may assist in adapting to irregular schedules.
• Delayed sleep-wake phase disorder (DSWPD): This circadian rhythm disorder is characterized by a habitual sleep onset and wake time that are delayed by two or more hours relative to conventional or socially acceptable times. Appropriately timed melatonin administration (typically in the early evening, several hours before desired bedtime) can advance the circadian phase and facilitate earlier sleep onset.
• Sleep disorders in neurodevelopmental conditions: Melatonin has demonstrated efficacy in improving sleep in children and adults with autism spectrum disorder (ASD), attention deficit hyperactivity disorder (ADHD), and intellectual disabilities, where sleep disturbances are highly prevalent and significantly impact quality of life.

The clinical efficacy of melatonin for insomnia has been evaluated in numerous randomized controlled trials and meta-analyses. A comprehensive meta-analysis published in PLoS ONE (Ferracioli-Oda et al., 2013) analyzed 19 studies involving 1,683 participants and found that exogenous melatonin significantly reduced sleep onset latency by an average of 7.06 minutes, increased total sleep time by 8.25 minutes, and improved overall sleep quality as measured by validated subjective scales. While these absolute improvements may appear modest, they are clinically meaningful for many patients, particularly when considered alongside melatonin's favorable safety profile and low risk of adverse effects compared with traditional hypnotics.

What Should You Know Before Taking Melatan?

Contraindications

Melatan is contraindicated in individuals with known hypersensitivity (allergy) to melatonin or to any of the excipients in the tablet formulation. While serious allergic reactions to melatonin are exceptionally rare, any previous allergic response to a melatonin-containing product should be reported to your healthcare provider before initiating treatment. Symptoms of hypersensitivity may include skin rash, itching, swelling (particularly of the face, lips, tongue, or throat), or difficulty breathing.

Melatonin is primarily metabolized in the liver by the cytochrome P450 enzyme CYP1A2. Patients with significant hepatic impairment (severe liver disease) may have substantially impaired melatonin clearance, leading to elevated plasma levels and potentially increased side effects. Melatan is therefore not recommended in patients with severe hepatic insufficiency. Patients with mild to moderate liver impairment should use melatonin with caution and under close medical supervision, as dose adjustments may be necessary.

Warnings and Precautions

Before starting Melatan, discuss the following conditions with your healthcare provider:

• Autoimmune disorders: Melatonin has immunomodulatory properties and may stimulate immune function. Although clinical evidence is limited, there is a theoretical concern that exogenous melatonin could exacerbate autoimmune conditions such as rheumatoid arthritis, systemic lupus erythematosus (SLE), multiple sclerosis, or inflammatory bowel disease. Patients with autoimmune disorders should use melatonin only under medical supervision.
• Epilepsy and seizure disorders: Some experimental data suggest that melatonin may lower the seizure threshold in certain contexts, although other studies have suggested a protective effect. Given the conflicting evidence, patients with epilepsy should use melatonin cautiously and with their neurologist's approval.
• Diabetes mellitus: Melatonin may affect glucose metabolism and insulin sensitivity. MT2 receptors are expressed on pancreatic beta cells, and genetic variants in the MTNR1B gene have been associated with altered glucose homeostasis. Diabetic patients should monitor blood glucose more closely when initiating melatonin therapy, as adjustments to antidiabetic medications may occasionally be needed.
• Depression: Melatonin should be used with caution in patients with depression, as the relationship between melatonin and mood regulation is complex. While some evidence suggests that melatonin agonists may have antidepressant properties, patients should report any worsening of mood symptoms during treatment.

Pregnancy and Breastfeeding

Melatan should not be used during pregnancy unless specifically advised by a doctor. There is insufficient clinical data on the use of exogenous melatonin in pregnant women. Animal reproductive studies have not demonstrated direct teratogenic effects, but melatonin crosses the placenta and may influence fetal circadian rhythm development. As a precautionary measure, women who are pregnant or planning to become pregnant should avoid melatonin supplements and discuss alternative approaches to managing sleep problems with their healthcare provider. Non-pharmacological interventions such as cognitive behavioral therapy for insomnia (CBT-I) and sleep hygiene optimization are generally preferred during pregnancy.

Melatonin is naturally present in human breast milk, with concentrations following a circadian pattern (higher at night, lower during the day). This physiological melatonin transmission is believed to play a role in establishing the infant's developing circadian rhythm. However, the effect of exogenous melatonin supplementation on breast milk melatonin levels and the breastfed infant has not been adequately studied. Women who are breastfeeding should consult their doctor before using Melatan and consider whether the benefits of treatment outweigh the potential risks to the nursing infant.

Driving and Operating Machinery

Melatan may cause drowsiness and reduced alertness, particularly in the hours immediately following ingestion. Patients should be advised not to drive, operate heavy machinery, or engage in activities requiring full alertness for approximately five hours after taking the medication. The drowsiness effect is generally mild at the recommended 1 mg dose but may be more pronounced in some individuals, particularly when treatment is first initiated. If you experience significant next-day drowsiness, consult your doctor about adjusting the timing or dose of your medication.

Alcohol

Alcohol consumption should be avoided while taking Melatan. Alcohol can reduce the effectiveness of melatonin in promoting sleep and may interfere with normal sleep architecture, leading to fragmented, poor-quality sleep. Additionally, the combination of alcohol and melatonin may increase drowsiness and impair cognitive function more than either substance alone. Patients should be advised to abstain from alcohol in the hours before bedtime when using Melatan.

How Does Melatan Interact with Other Drugs?

Melatonin is primarily metabolized in the liver by the cytochrome P450 enzyme CYP1A2, with minor contributions from CYP2C19. This metabolic pathway means that drugs which inhibit or induce CYP1A2 can significantly affect melatonin blood levels and, consequently, its therapeutic efficacy and side effect profile. Understanding these interactions is essential for safe and effective use of Melatan.

Major Interactions

The most clinically significant interaction involves fluvoxamine, a selective serotonin reuptake inhibitor (SSRI) used primarily for the treatment of obsessive-compulsive disorder (OCD) and depression. Fluvoxamine is one of the most potent inhibitors of CYP1A2 known. Co-administration with melatonin results in dramatically increased melatonin plasma concentrations, with studies showing increases of up to 12- to 17-fold. This degree of elevation can lead to excessive and prolonged sedation, severe drowsiness, impaired coordination, and other intensified side effects. The concurrent use of fluvoxamine and melatonin should therefore be avoided.

Moderate Interactions

Other Considerations

Patients who smoke tobacco should be aware that smoking induces CYP1A2 activity, which accelerates melatonin metabolism and may reduce its effectiveness. Conversely, if a patient stops smoking during melatonin treatment, plasma melatonin levels may rise as CYP1A2 activity normalizes, potentially leading to increased sedation. Dose adjustments may be appropriate when starting or stopping smoking during Melatan therapy.

Melatonin may have additive sedative effects when combined with other central nervous system depressants, including alcohol, benzodiazepines, Z-drugs (zolpidem, zopiclone), antihistamines, opioids, and certain antidepressants with sedative properties (such as mirtazapine or trazodone). While these combinations are not strictly contraindicated, patients and prescribers should be vigilant for signs of excessive sedation, particularly when melatonin is added to an existing regimen that includes CNS depressants.

Regarding anticoagulants, there are isolated case reports suggesting that melatonin may enhance the anticoagulant effects of warfarin. Although the mechanism is unclear and the clinical significance is uncertain, patients on warfarin or other vitamin K antagonists should have their International Normalized Ratio (INR) monitored more closely when initiating or discontinuing melatonin therapy.

What Is the Correct Dosage of Melatan?

Melatan should always be used exactly as prescribed by your doctor. The dosage, timing, and duration of treatment may vary depending on the specific sleep disorder being treated, patient age, other medications, and individual response to therapy. Do not exceed the prescribed dose, as higher doses of melatonin do not necessarily produce greater sleep benefits and may lead to increased side effects or paradoxical wakefulness.

Adults

The standard recommended dose of Melatan for adults is one 1 mg tablet taken approximately 30 minutes to one hour before the intended bedtime. The tablet should be swallowed whole with water and should not be crushed, chewed, or dissolved, as this may alter the release characteristics and absorption kinetics of the medication. Taking Melatan after a light meal or snack is generally recommended, as food may reduce gastrointestinal side effects, although it may also slightly delay the onset of action.

For the management of primary insomnia in adults aged 55 and older, treatment is typically initiated for a period of up to 13 weeks. The prescribing physician may recommend shorter treatment durations for mild or transient insomnia, or may consider extending treatment if clinically warranted. Periodic reassessment of the need for continued treatment is recommended, as some patients may achieve sustained improvement in sleep quality after a defined course of therapy.

Children and Adolescents

Melatan 1 mg tablets are primarily intended for adult use. However, melatonin is increasingly prescribed off-label for children with sleep disturbances, particularly those associated with neurodevelopmental conditions. In 2018, the EMA approved a pediatric prolonged-release melatonin formulation (not Melatan specifically) for children and adolescents aged 2–18 years with insomnia associated with autism spectrum disorder (ASD) or Smith-Magenis syndrome. Pediatric dosing should only be determined by a specialist and typically starts at lower doses (0.5–1 mg) with gradual titration based on clinical response.

Parents and caregivers should not administer Melatan to children without explicit medical guidance, as the appropriate dose, formulation, and safety profile may differ from adult use. Long-term safety data for melatonin use in children remain limited, and ongoing monitoring by a healthcare professional is essential.

Elderly Patients

The standard 1 mg dose of Melatan is appropriate for elderly patients and is specifically designed with this population in mind. Older adults often have reduced endogenous melatonin production and may benefit most from exogenous supplementation. No routine dose adjustment is required based on age alone. However, elderly patients are more likely to have hepatic impairment, renal impairment, or to be taking multiple medications that may interact with melatonin. A comprehensive medication review should be conducted before initiating therapy, and patients should be monitored for signs of excessive sedation or next-day drowsiness.

Missed Dose

If you forget to take Melatan at your usual time but it is still your bedtime, you may take the missed dose as long as you can still remain in bed for a full night's sleep. If you have already fallen asleep or it is past your usual bedtime, skip the missed dose entirely and take your next dose at the regular time the following evening. Do not take a double dose to make up for a forgotten dose. Missing an occasional dose of melatonin will not cause withdrawal symptoms or rebound insomnia.

Overdose

Melatonin has a wide therapeutic index, and acute overdose is generally not considered life-threatening. Reported symptoms of melatonin overdose include excessive drowsiness, headache, dizziness, nausea, and impaired coordination. In cases of significant overdose, symptomatic and supportive treatment is appropriate. There is no specific antidote for melatonin overdose. If you suspect that you or someone else has taken more Melatan than prescribed, contact your local poison control center or seek medical attention. Melatonin is cleared relatively quickly from the body (half-life approximately 3.5–4 hours), so symptoms are typically self-limiting.

What Are the Side Effects of Melatan?

Like all medicines, Melatan can cause side effects, although not everybody gets them. Melatonin is generally very well tolerated, with a safety profile that compares favorably to most other pharmacological treatments for insomnia. The majority of reported side effects are mild to moderate in intensity and tend to resolve on their own without the need for treatment discontinuation. Clinical trials and post-marketing surveillance data have established the following side effect profile for oral melatonin:

It is important to note that many of the side effects listed above were reported infrequently in clinical trials and post-marketing surveillance. The overall incidence of adverse effects with melatonin at recommended doses is low, and discontinuation rates due to side effects in clinical trials have been comparable to placebo. A 2015 systematic review and meta-analysis published in the journal Sleep Medicine Reviews confirmed that melatonin does not significantly increase the risk of adverse events compared with placebo in short-term use.

One of the most important distinctions between melatonin and traditional hypnotics is the absence of next-day residual effects (hangover effect) at the recommended 1 mg dose. Unlike benzodiazepines and Z-drugs, which can impair psychomotor performance, memory consolidation, and reaction time the morning after use, melatonin at therapeutic doses has not been shown to produce clinically significant next-morning impairment. This is particularly relevant for elderly patients, in whom medication-related drowsiness, impaired balance, and falls are major safety concerns.

Furthermore, extensive clinical experience and research have demonstrated that melatonin does not produce the tolerance (need for increasing doses to achieve the same effect), physical dependence, or withdrawal symptoms that are associated with prolonged use of benzodiazepines, barbiturates, and Z-drugs. When Melatan is discontinued, there is no characteristic rebound insomnia — a phenomenon in which sleep quality temporarily worsens beyond baseline levels after stopping a hypnotic medication. This favorable discontinuation profile makes melatonin well suited for intermittent or course-based use.

How Should You Store Melatan?

Proper storage of Melatan is important to ensure the medication retains its potency and safety throughout its shelf life. Melatonin can degrade when exposed to light, heat, or moisture, which may reduce its effectiveness. The following storage guidelines should be followed:

• Temperature: Store at room temperature, below 25°C (77°F). Do not refrigerate or freeze the tablets unless specifically directed to do so by the packaging or your pharmacist.
• Light protection: Keep the tablets in the original blister packaging or container until use. Melatonin is sensitive to light, and prolonged exposure may lead to degradation of the active substance.
• Moisture: Store in a dry place. Do not store in the bathroom or near sinks where humidity may be high.
• Child safety: Keep Melatan out of the sight and reach of children. The tablets may be confused with sweets or vitamins and could be accidentally ingested by young children.
• Expiry date: Do not use Melatan after the expiry date stated on the packaging (usually printed as EXP followed by month and year). The expiry date refers to the last day of that month.

Do not dispose of medicines via household waste or down the drain. Ask your pharmacist how to dispose of medicines you no longer use or that have expired. These measures will help protect the environment and prevent accidental ingestion.

What Does Melatan Contain?

The active substance in Melatan is melatonin (N-acetyl-5-methoxytryptamine), a synthetic form that is chemically identical to the melatonin naturally produced by the human pineal gland. Each tablet contains precisely 1 mg of melatonin. Synthetic melatonin is preferred over animal-derived sources (which were used historically) because it eliminates the risk of contamination with animal proteins or infectious agents and allows for precise, standardized dosing.

In addition to the active ingredient, Melatan tablets contain excipients (inactive ingredients) that are necessary for the manufacture, stability, and physical properties of the tablet. While excipient compositions may vary slightly between manufacturers and formulations, common excipients in melatonin tablets may include:

• Tablet core: Lactose monohydrate or microcrystalline cellulose (fillers), croscarmellose sodium or sodium starch glycolate (disintegrants), magnesium stearate (lubricant), colloidal anhydrous silica (glidant)
• Tablet coating: Hypromellose (hydroxypropyl methylcellulose), titanium dioxide, macrogol (polyethylene glycol), and potentially iron oxide pigments for coloring

Patients with known allergies or intolerances to any excipient should review the full list of ingredients on the product packaging or patient information leaflet before taking Melatan. In particular, patients with lactose intolerance should be aware that some melatonin formulations contain lactose monohydrate as a filler. If you are uncertain about the ingredients, consult your pharmacist.